CONTENTS

SPECIAL SECTION ON PREDICTION OF HUMAN PHARMACOKINETIC PARAMETERS FROM IN VITRO SYSTEMS

Prediction of Human Pharmacokinetics in 2013 and Beyond. J. Brian Houston 1973

A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. Li Di, Bo Feng, Theunis C. Goosen, Yurong Lai, Stefanus J. Steyn, Manthena V. Varma, and R. Scott Obach 1975

Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development. Carole E. Shardlow, Grant T. Generaux, Aarti H. Patel, Guoying Tai, Thuy Tran, and Jackie C. Bloomer 1994

CYP2B6 Pharmacogenetics—Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling. Cong Xu, Sara K. Quinney, Yingying Guo, Stephen D. Hall, Lang Li, and Zeruesenay Desta 2004

In Vitro P-glycoprotein Efflux Ratio Can Predict the In Vivo Brain Penetration Regardless of Bioavailability of Pharmacokinetics Drugs Disposition Classification System Class. Ryota Kikuchi, Sonia M. de Morais, and J. Cory Kalvass 2012


Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac. Tom S. Chan, Hongbin Yu, Amanda Moore, Salman R. Khetani, and Donald Tweedie 2024


SHORT COMMUNICATION


ARTICLES

N-Acetylation of Etamicastat, a Reversible Dopamine-β-Hydroxylase Inhibitor. Ana I. Loureiro, Carlos Fernandes-Lopes, Maria João Bonfáico, Lyndon C. Wright, and Patrício Soares-da-Silva 2081